The Belport Company, Inc DBA Gingi-Pak

Form 483 issued November 12, 2021 · Camarillo, California

Investigator
Taichun Qin
Observations
7
Pages
6
FEI number
2014676

In short: On November 12, 2021, FDA issued a Form 483 with 7 observations to The Belport Company, Inc DBA Gingi-Pak in Camarillo, California (FEI 2014676). The investigator was Taichun Qin. Most observations concern production and quality system.

At a glance

Observations span 4 systems, led by production.

Production3
Quality system1
Laboratory controls1
Packaging & labeling1
Other1

What FDA observed

Preview: the opening words of each observation
  1. 01

    Procedures designed to prevent objectionable microorganisms in drug products not required to be…

  2. 02

    Written records of investigations into unexplained discrepancies and the failure of a batch or any of…

  3. 03

    Written production and process control procedures are not followed in the execution of production…

  4. 04

    There is no written testing program designed to assess the stability…

3 more observations

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at The Belport Company, Inc DBA Gingi-Pak?

FDA listed 7 observations on this Form 483, mostly about production, quality system and laboratory controls. The opening words of each observation are shown on this page.

Who inspected The Belport Company, Inc DBA Gingi-Pak?

Taichun Qin is named on this Form 483. Each investigator has a profile showing what they cite most.

When was The Belport Company, Inc DBA Gingi-Pak inspected by FDA?

This Form 483 is dated November 12, 2021.

How do I get the full Form 483 for The Belport Company, Inc DBA Gingi-Pak?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free